Passive smoking and thiopurine methyl transferase genotyping in 6-mercaptopurine-induced myelosuppression in Egyptian children with acute lymphoblastic leukemia

Hanan Abdelgawad Mohamed Hegazy; Hend Rashad; Mai S. Saleh

doi:10.53730/ijhs.v6nS3.9258

Authors

Hanan Abdelgawad Mohamed Hegazy Assistant researcher, Environmental and Occupational medicine Department, National Research Centre, Egypt
Hend Rashad Professor of Environmental Health, Environmental and Occupational medicine Department, National Research Centre, Egypt
Mai S. Saleh Researcher, Environmental and Occupational medicine Department, National Research Centre, Egypt

Keywords:

passive smoking, thiopurine methyl transferase, 6-mercaptopurine, acute lymphoblastic leukemia, myelosuppression

Abstract

6-mercaptopurine (6-MP) is a crucial component drug used to treat childhood acute lymphoblastic leukemia (ALL) in the maintenance phase. Thiopurine S-methyltransferase (TPMT) is an enzyme that metabolizes thiopurine drugs like 6-MP. In patients taking thiopurine medications, lack of TPMT activity is linked to an increased risk of myelosuppression. Patients with TPMT polymorphisms are more likely to develop mercaptopurine-induced myelosuppression. The goal of this study was to see how passive smoking and TPMT genetic variations affected 6-MP-induced myelosuppression in Egyptian ALL children. This study included 100 children: 50 with acute lymphoblastic leukemia in the maintenance phase of treatment who had a history of passive smoking and 50 age-matched healthy controls. 6-MP was given to patients in the maintenance phase, and myelosuppression was monitored at the end of this phase by comparing WBC counts to those obtained at the start of treatment. After six months of 6-MP administration, there was no significant association between cotinine levels and WBC count (as evidence of myelosuppression), although there was a significant correlation between TPMT genotypes and WBC count, with 75% of hetero genotype patients suffering from severe declines in WBC count and 91% of wild genotype people undergoing mild to moderate decreases in WBC count.

Downloads

Download data is not yet available.

References

Adam de Beaumais, T., Fakhoury, M., Medard, Y., Azougagh, S., Zhang, D.,Yakouben, K.,& Jacqz-Aigrain, E. (2011): Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol.; 71(4): 575–584.

Borssén, M. , Nordlund, J., Haider, Z., Landfors, M. , Larsson, P., Kanerva, J., Schmiegelow, K., Flaegstad, T., Jónsson, ÓG., , Frost, B., Palle, J., Forestier, E., Heyman, M., Hultdin, M., Lönnerholm, G., & Degerman, S. (2018). DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia. Clinical Epigenetics; 10:31.

Cárceles-Álvarez, A., Ortega-García, J., López-Hernández, F., Fuster-Soler, J., Ramis, R., Kloosterman, N., Castillo, L., Sánchez-Solís, M., Claudio, L., Ferris-Tortajada, J.(2019). Secondhand smoke: A new and modifiable prognostic factor in childhood acute lymphoblastic leukemias. Environ. Res.,Volume 178(108689): 0013-9351.

Cogliano, VJ., Baan, R., Straif, K., Grosse, Y., Lauby-Secretan, B., El Ghissassi, F., Bouvard, V., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., & Wild, CP.(2011). Preventable Exposures Associated With Human Cancers. J Natl Cancer Inst.; 103(24): 1827–1839.

Conneely, SE., Cooper, SL. & Rau, RE. (2020). Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia. Front Oncol.; 10: 1129.

Coulter, W. (1956). High speed automatic blood cell counter and cell size analyzer. In Cytometry (3rd edition). Waltham, MA.: Elsevier, ( updated 2021).

de Smith, AJ., Kaur, M., Gonseth, S., Endicott, A., Selvin, S., Zhang L., Roy, R., Shao, X. Hansen, HM., Kang, AY., Walsh, KM., Dahl, GV., McKean-Cowdin, R., Metayer, C., & Wiemels JL. (2017). Correlates of prenatal and early-life tobacco smoke exposure and frequency of common gene deletions in childhood acute lymphoblastic leukemia. Cancer Res.; 77(7): 1674–1683.

Dean, L. & Kane, M.(2020). Mercaptopurine Therapy and TPMT and NUDT15 Genotype 2012 Sep 20 [Updated 2020 Oct 26]. In: Pratt V.M., Scott S.A., Pirmohamed, M., Esquivel, B., Kane, MS., Kattman, BL., & Malheiro, A.J., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.Bookshelf URL: https://www.ncbi.nlm.nih.gov/books.

Dresden, D. & Ranchod, Y. ( 2021). What are different types of leukemia? Medical News Today, www.medicalnewstoday.com.

El-kaffash, D., Hassab, H., AbouZeid, A., Swelem, R., & Tahoun, M. (2014). TPMT gene polymorphism detection by conventional PCR in pediatric acute lymphoblastic leukemia and its toxic effect. Egypt. J. Haematol.; 39:86–90.

El-Rashedy, FH., Ragab, SM., Dawood, AA. & Temraz, SA.(2015). Clinical implication of thiopurine methyltransferase polymorphism in children with acute lymphoblastic leukemia: A preliminary Egyptian study. Indian J Med Paediatr Oncol.;36 (4): 265-270.

Gritz, ER., Dresler, C., & Sarna, L. (2005). Smoking, the missing drug interaction in clinical trials: ignoring the obvious Cancer Epidemiol. Biomark. Prev.; pp. 2287-2293.

Jacob, P., Benowitz, NL., Destaillats, H., Gundel, L., Hang, B., Martins-Green, M., Matt, GE., Quintana, PJ., Samet, JM., Schick, SF., Talbot, P., Aquilina, NJ., Hovell MF., Mao, JH., Whitehead, TP. (2017). Thirdhand smoke: new evidence, challenges, and future directions. Chem. Res. Toxicol.; pp. 270-294.

Jantararoungtong, T., Wiwattanakul, S., Tiyasirichokchai, R. , Prommas, S. , Sukprasong, R., Koomdee, N., Jinda, P., Rachanakul, J. , Nuntharadthanaphong, N., Pakakasama, S. , Anurathapan, U. , Hongeng, S. & Sukasem, C. (2021). TPMT*3C as a Predictor of 6-Mercaptopurine-Induced Myelotoxicity in Thai Children with Acute Lymphoblastic Leukemia, J. Pers. Med. 783:1-16.

Kouwenberg, T., van den Bosch, B., Bierau, J., Te Loo, D., Coenen. M., & Hagleitner, M. (2020). Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment. J. Pediatr. Hematol. Oncol. ;42(2):94-97.

Lyengar, V. & Shimanovsky, A. (2021). Leukemia. In: StatPearls [Internet]. Treasure Island (FL). NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Orgel, E. & Bhojwani, D. (2017). Medical supportive care for treatment-related toxicity in childhood ALL. Vora, A. (Ed.), Childhood Acute Lymphoblastic Leukemia (first ed.), Springer International Publishing, Cham, Switzerland, pp. 299-321.

Peregud-Pogorzelski, J., Tetera-Rudnicka, E., Kurzawski, M., Brodkiewicz, A., Adrianowska, N., Mlynarski, W., Januszkiewicz, D., & Drozdzik, M. (2011). Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: The Polish multicenter analysis. Pediatr Blood Cancer; 57:578-582.

Pui, C., Campana, D., Pei, D., Bowman, WP., Sandlund, JT., Kaste, SC., Ribeiro, RC., Rubnitz, JE., Raimondi, SC., Onciu, M., Coustan-Smith, E., Kun, LE., Jeha, S., Cheng, C., Howard, SC., Simmons, V., Bayles, A., Metzger, ML., Boyett, JM., Leung,W., Handgretinger, R., Downing, JR., Evans, WE., & Relling, MV. (2009). Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med.;360:2730-2741.

Wielkoszynski, T., Tyrpien, K. & Szumska, M. )2009(. The enzyme-linked immunosorbent assay (ELISA) method for nicotine metabolites determination in biological fluids. J. Pharm. Biomed. Anal.; 49:1256–1260.